Add as a preferred source on GoogleQuoin Pharmaceuticals Posts $0.97 Q3 GAAP Loss Per ADS
Net loss widened to $4.87 million year over year, while cash and investments totaled $33.2 million at Sept. 30.
Quoin Pharmaceuticals Ltd. posted a third-quarter 2026 GAAP loss of $0.97 per American depositary share (ADS), as its net loss and operating expenses both increased from a year earlier.
Net loss reached $4.87 million, compared with $3.95 million in the year-ago quarter. Operating expenses rose to $4.92 million from $4.02 million.
Research and development costs were $2.66 million, up from $2.28 million. General and administrative expenses increased to $2.27 million from $1.74 million.
Quoin had $10.1 million in cash and cash equivalents and $23.1 million in investments as of Sept. 30. The company develops treatments for rare and orphan diseases and had not commercialized a product or generated revenue.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.